Titan Pharmaceuticals Inc
TTNPDelisted Oct 2, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000910267
Titan Pharmaceuticals Inc was delisted on Oct 2, 2025; its insiders filed their last Form 4 on Oct 8, 2025; 18 institutions reported holding it in 13F filings for Q3 2025, worth $107.1K in total; no superinvestor held it.
13F holders, Q4 2023
Institutional positions in Titan Pharmaceuticals Inc as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- −3 vs. Q3 2023
- Shares held
- 1.01M
- −47.7K (−4.5%) vs. Q3 2023
- Total value
- $408.2K
- −$89.6K (−18.0%) vs. Q3 2023
- New holders
- 2
- 2 more added
- Sold out
- 5
- 7 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TTNP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 5 | $69 |
| Q1 2026 | 6 | $130 |
| Q4 2025 | 4 | $154 |
| Q3 2025 | 18 | $107.1K |
| Q2 2025 | 20 | $158.3K |
| Q1 2025 | 17 | $51.9K |
| Q4 2024 | 15 | $9.41K |
| Q3 2024 | 16 | $88.5K |
| Q2 2024 | 18 | $179.3K |
| Q1 2024 | 17 | $230.0K |
| Q4 2023 | 24 | $408.2K |
| Q3 2023 | 27 | $497.8K |
| Q2 2023 | 25 | $632.7K |
| Q1 2023 | 22 | $787.4K |
| Q4 2022 | 23 | $757.9K |
| Q3 2022 | 21 | $1.14M |
| Q2 2022 | 24 | $371.0K |
| Q1 2022 | 24 | $1.24M |
| Q4 2021 | 24 | $430.0K |
| Q3 2021 | 22 | $722.0K |
| Q2 2021 | 23 | $1.51M |
| Q1 2021 | 24 | $988.1K |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Titan Pharmaceuticals Inc; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Truist Financial Corp | 625,089 | $257.8K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 135,310 | $56.0K | 0.00% | −400−0.3% | Reduced |
| Vanguard Group Inc | 82,051 | $33.8K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 87,945 | $29.0K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 38,287 | $15.8K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 19,596 | $8.08K | 0.00% | −42,549−68.5% | Reduced |
| Millennium Management LLC | 15,113 | $6.23K | 0.00% | +15,113 | New |
| Tower Research Capital LLC (TRC) | 1,544 | $638 | 0.00% | −29−1.8% | Reduced |
| Level Financial Advisors, Inc. | 987 | $407 | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 230 | $95 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 207 | $85 | 0.00% | +1+0.5% | Added |
| JPMorgan Chase & Co | 154 | $64 | 0.00% | −3−1.9% | Reduced |
| Wells Fargo & Company | 89 | $37 | 0.00% | +5+6.0% | Added |
| BlackRock Inc. | 60 | $25 | 0.00% | 00.0% | Unchanged |
| Global Wealth Strategies & Associates | 40 | $17 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 37 | $13 | 0.00% | −13−26.0% | Reduced |
| Westside Investment Management, Inc. | 4 | $2 | 0.00% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 4 | $2 | 0.00% | 00.0% | Unchanged |
| GWM Advisors LLC | 4 | $2 | 0.00% | +4 | New |
| Morgan Stanley | 3 | $1 | 0.00% | −13−81.3% | Reduced |
| UBS Group AG | 2 | $1 | 0.00% | −2−50.0% | Reduced |
| Caldwell Sutter Capital, Inc. | 2 | $1 | 0.00% | 00.0% | Unchanged |
| Newbridge Financial Services Group, Inc. | 2 | $1 | 0.00% | 00.0% | Unchanged |
| St Germain D J Co Inc | 1 | $0 | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −19,705−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −62−100.0% | Sold out |
| Nemes Rush Group LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| McClarren Financial Advisors, Inc. | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| Cape Investment Advisory, Inc. | 0 | $0 | 0.00% | −1−100.0% | Sold out |